UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

UCB’s ongoing work and unwavering focus keep people living with MG at the heart of everything we do, and we are committed to finding solutions for rare diseases, like MG, with a high degree of patient need by delivering purposeful innovations and differentiated solutions, creating value that cannot be expressed in numbers alone. 

Through UCB’s Digital Business Transformation, we are committed to unleashing the power of digital innovation and enabling solutions that allow patients to live the lives they choose, now and in the future. 

This Hispanic Heritage Month, we are showcasing the story of Alicia Clark, District Sales Lead, Rheumatology, as it is an inspiration to those around her both inside and outside UCB.

UCB’s robust global R&D response during COVID-19 focused on our patients, employees, and our communities. Read more on our overall approach from UCB's Chief Medical Officer, Iris Loew-Friedrich.  

Each year, UCB has the honor of awarding our UCB Family Epilepsy Scholarship to deserving individuals living with epilepsy, their family members, and caregivers to help them fulfill their dreams. We realize that to truly make an impact on patients’ lives, we must go beyond developing and delivering medicines, and we are committed to helping patients and their families receive the financial support they need to live their best lives possible.

This August, the theme for Psoriasis Action Month is ‘All of Us.’ UCB is joining the National Psoriasis Foundation to shine light on the condition’s impact on diverse populations, and celebrate the diversity and inclusivity of the psoriasis community. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 

As part of Psoriasis Action Month, Camille Lee, Head of U.S. Immunology at UCB, shares how UCB is helping find and bridge gaps in psoriatic disease care. 

Tomorrow is National Intern Day 2021! We are pleased to continue our mission of investing in the next generation of the workforce by welcoming 32 student interns to our second virtual internship program.